Novel approaches to lipid lowering: what is on the horizon?

This publication has 18 references indexed in Scilit:

• Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
  The American Journal of Cardiology, 2001
• Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
  Atherosclerosis, 2000
• A target for cholesterol absorption inhibitors in the enterocyte brush border membrane
  Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2000
• Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
  The American Journal of Cardiology, 2000
• Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
  International Journal of Cardiology, 1999
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Triglyceride as a risk factor for coronary artery disease
  The American Journal of Cardiology, 1998
• Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients
  The American Journal of Cardiology, 1998
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995